“What’s Up in Biotech_” Near-Term Catalysts_Events Ahead

Summary of Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology industry, specifically highlighting upcoming catalysts and events expected in the first half of 2025 [2][6][7]. Key Catalysts and Events Very High Impact (>30%) - ACRV: ACR-368 Phase 2 pipeline update expected in H1:25 [6] - ALDX: PDUFA date for reproxalap in dry eye disease on April 2, 2025 [6] - ATYR: Efzofitimod Phase 2b interim data in Q2:25 [6] - CVAC: CV19 vaccine US IP trial hearing on validity in March 2025 [6] - SGMO: Business development deal for Fabry expected in Q1:25 [6] High Impact (10-30%) - ACRS: ATI-2138 Phase 2a AD topline data expected in H1:25 [8] - ALNY: Vutrisiran PDUFA for ATTR-CM on March 23, 2025 [8] - INCY: Pivotal Phase 3 data of povorcitinib in HS expected in H1:25 [10] - KALV: PDUFA for Sebetralstat as the first oral on-demand HAE therapy on June 17, 2025 [10] Medium Impact (5-10%) - ACRS: BSI-045 Phase 2 AD initiation in Q1:25 [10] - GLUE: Updated Phase 1/2 data of GSPT1 degrader MRT-2359 in MYC-driven tumors in Q1:25 [10] - IDYA: Phase 2 neoadjuvant UM data expected in H1:25 [10] Modest Impact (<5%) - ACRS: BSI-045 Phase 2 asthma data in China expected in Q1:25 [12] - ALT: Pemvidutide IND filing and Phase 2 start in H1:25 [12] - JAZZ: Potential judge's decision on ODE appeals in H1:25 [12] Company-Specific Disclosures - Jefferies is acting as a financial advisor to Abeona Therapeutics in the review of strategic options [27]. - Jefferies is serving as a financial advisor to Intra-Cellular Therapies, Inc. in their acquisition by Johnson & Johnson [27]. - Analysts have disclosed personal equity positions in various companies, including Eli Lilly & Company and Vertex Pharmaceuticals [29]. Important Considerations - The report emphasizes that the catalysts listed are not exhaustive and are intended to spur discussion among investors [2]. - The report is intended for Jefferies clients only, and unauthorized distribution is prohibited [12]. This summary captures the essential points from the conference call, focusing on the biotechnology industry and the upcoming catalysts that could impact stock movements.